Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Neuropace Inc (NPCE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: NPCE (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.12
1 Year Target Price $17.12
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 181.14% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 312.24M USD | Price to earnings Ratio - | 1Y Target Price 17.12 |
Price to earnings Ratio - | 1Y Target Price 17.12 | ||
Volume (30-day avg) 8 | Beta 2.04 | 52 Weeks Range 5.45 - 18.98 | Updated Date 07/14/2025 |
52 Weeks Range 5.45 - 18.98 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -29.42% | Operating Margin (TTM) -22.85% |
Management Effectiveness
Return on Assets (TTM) -11.52% | Return on Equity (TTM) -128.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 319131767 | Price to Sales(TTM) 3.7 |
Enterprise Value 319131767 | Price to Sales(TTM) 3.7 | ||
Enterprise Value to Revenue 3.79 | Enterprise Value to EBITDA -16.94 | Shares Outstanding 32798500 | Shares Floating 21320340 |
Shares Outstanding 32798500 | Shares Floating 21320340 | ||
Percent Insiders 2.75 | Percent Institutions 85.67 |
Upturn AI SWOT
Neuropace Inc
Company Overview
History and Background
NeuroPace, Inc. was founded in 1997 and is a commercial-stage medical device company focused on developing, manufacturing, and marketing RNS System for patients with epilepsy.
Core Business Areas
- RNS System: NeuroPace's core business revolves around the RNS (Responsive Neurostimulation) System, a closed-loop brain-computer interface designed to prevent seizures by monitoring brain activity and delivering targeted electrical stimulation.
Leadership and Structure
NeuroPace is led by a management team with expertise in medical devices and neuroscience. The company has a structured organizational hierarchy with departments focusing on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- RNS System: The RNS System is NeuroPace's primary product. It is an implantable neurostimulator used for treating refractory epilepsy. Market share data is difficult to precisely quantify due to the specific nature of the target patient population (those who don't respond to medication). Competitors include companies providing alternative epilepsy treatments such as vagus nerve stimulation (VNS) from LivaNova (LIVN) and surgical resection.
Market Dynamics
Industry Overview
The epilepsy treatment market is characterized by ongoing innovation in devices and therapies, a large patient population, and increasing awareness of advanced treatment options. The market is competitive, with pharmaceutical companies, medical device manufacturers, and research institutions all contributing to advancements.
Positioning
NeuroPace is positioned as a technology leader in responsive neurostimulation for epilepsy. Its RNS System offers a unique closed-loop approach, potentially providing more personalized and effective seizure control compared to traditional methods. The company aims to address a segment of the epilepsy market where other treatments have failed.
Total Addressable Market (TAM)
The total addressable market for neuromodulation in epilepsy is estimated to be in the billions of dollars. NeuroPace is focused on capturing a significant share of this market by targeting patients with drug-resistant focal epilepsy who are not suitable candidates for surgical resection.
Upturn SWOT Analysis
Strengths
- Innovative technology (RNS System)
- Targeted therapy for drug-resistant epilepsy
- Strong intellectual property portfolio
- Clinical data supporting efficacy
- Direct brain monitoring capability
Weaknesses
- High cost of RNS System
- Invasive procedure required for implantation
- Reliance on a single product
- Limited market awareness
- Reimbursement challenges
Opportunities
- Expanding indications for RNS System
- Increasing adoption by epilepsy centers
- Developing partnerships with neurologists
- Improving patient access through reimbursement
- Exploring applications in other neurological disorders
Threats
- Competition from alternative epilepsy treatments
- Technological advancements by competitors
- Regulatory hurdles and delays
- Adverse events associated with RNS System
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- LIVN
Competitive Landscape
NeuroPace's RNS System offers a unique advantage in responsive neurostimulation, but it faces competition from other established neuromodulation technologies like VNS (LivaNova) and traditional epilepsy treatments. NeuroPace needs to continue demonstrating the clinical benefits and cost-effectiveness of its system to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Analyze NeuroPace's historical revenue growth and patient adoption rates to understand its past performance. Look at the SEC filings for past performance of the company.
Future Projections: Refer to analyst reports and company guidance for future growth projections for NeuroPace.
Recent Initiatives: Identify recent strategic initiatives undertaken by NeuroPace, such as expanding sales teams, developing new partnerships, or launching clinical trials.
Summary
NeuroPace is a company focused on epilepsy treatment with its innovative RNS System. Its technology is potentially game-changing for patients with drug-resistant epilepsy, but its high cost and invasive procedure present challenges. Expanding market awareness, securing favorable reimbursement, and demonstrating clinical efficacy are crucial for NeuroPace to achieve long-term growth. competition from other epilepsy treatments always is a significant risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- NeuroPace Inc. SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Website
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is based on estimates and may not be precise. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuropace Inc
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2021-04-22 | CEO, President & Director Mr. Joel D. Becker | ||
Sector Healthcare | Industry Medical Devices | Full time employees 195 | Website https://www.neuropace.com |
Full time employees 195 | Website https://www.neuropace.com | ||
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.